当前位置: 首页 >> 检索结果
5409. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
作者: Silvio Danese.;Séverine Vermeire.;Wen Zhou.;Aileen L Pangan.;Jesse Siffledeen.;Susan Greenbloom.;Xavier Hébuterne.;Geert D'Haens.;Hiroshi Nakase.;Julian Panés.;Peter D R Higgins.;Pascal Juillerat.;James O Lindsay.;Edward V Loftus.;William J Sandborn.;Walter Reinisch.;Min-Hu Chen.;Yuri Sanchez Gonzalez.;Bidan Huang.;Wangang Xie.;John Liu.;Michael A Weinreich.;Remo Panaccione.
来源: Lancet. 2022年399卷10341期2113-2128页
There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative colitis. We assessed the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.
5413. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
作者: Marc Ferrante.;Remo Panaccione.;Filip Baert.;Peter Bossuyt.;Jean-Frederic Colombel.;Silvio Danese.;Marla Dubinsky.;Brian G Feagan.;Tadakazu Hisamatsu.;Allen Lim.;James O Lindsay.;Edward V Loftus.;Julián Panés.;Laurent Peyrin-Biroulet.;Zhihua Ran.;David T Rubin.;William J Sandborn.;Stefan Schreiber.;Ezequiel Neimark.;Alexandra Song.;Kristina Kligys.;Yinuo Pang.;Valerie Pivorunas.;Sofie Berg.;W Rachel Duan.;Bidan Huang.;Jasmina Kalabic.;Xiaomei Liao.;Anne Robinson.;Kori Wallace.;Geert D'Haens.
来源: Lancet. 2022年399卷10340期2031-2046页
There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy.
5414. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
作者: Geert D'Haens.;Remo Panaccione.;Filip Baert.;Peter Bossuyt.;Jean-Frederic Colombel.;Silvio Danese.;Marla Dubinsky.;Brian G Feagan.;Tadakazu Hisamatsu.;Allen Lim.;James O Lindsay.;Edward V Loftus.;Julian Panés.;Laurent Peyrin-Biroulet.;Zhihua Ran.;David T Rubin.;William J Sandborn.;Stefan Schreiber.;Ezequiel Neimark.;Alexandra Song.;Kristina Kligys.;Yinuo Pang.;Valerie Pivorunas.;Sofie Berg.;W Rachel Duan.;Bidan Huang.;Jasmina Kalabic.;Xiaomei Liao.;Anne Robinson.;Kori Wallace.;Marc Ferrante.
来源: Lancet. 2022年399卷10340期2015-2030页
Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.
5418. Violence against health-care workers in the Philippines.
作者: Michelle Ann B Eala.;Ethan Angelo S Maslog.;Janine Patricia G Robredo.;Raymond Joshua L San Pedro.;Paolo Victor N Medina.;Edelina P De la Paz.;Gideon Lasco.
来源: Lancet. 2022年399卷10340期2012-2013页 |